Business Wire

GenomOncology and Congenica Announce Collaborative Development of Novel Precision Oncology Solution

Share

Congenica, a UK-based digital health company that enables the rapid analysis and interpretation of genomic data, has selected the GenomOncology Precision Oncology Platform for the development of a novel ground-breaking CE-IVD Precision Oncology Solution.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220803005517/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Alistair Johnson is Chief Professional Services Officer at Congenica (Photo: Business Wire)

Driven by the increasing adoption of cancer genomics and the growing need to individualize therapeutic recommendations, Congenica is developing a fully automated data analysis application, aimed at transforming the usability and scalability of genomic data for routine oncology clinical practice.

To further enrich decision support capabilities for this novel precision oncology solution, Congenica is collaborating with GenomOncology to provide regional therapy recommendations.

GenomOncology’s Precision Oncology Platform is designed to harmonize the latest precision oncology information, which includes an extensive set of annotations and ontologies, as well as curated public, licensed, and proprietary content and data sets. By incorporating this comprehensive knowledgebase, Congenica will have improved access to curated, precision oncology information from the United States, United Kingdom, European Union, and others, to yield data-driven insights and recommendations within their CDS.

Alistair Johnson, Chief Professional Services Officer at Congenica, said: “This collaboration signifies the expansion of Congenica’s Clinical Decision Support (CDS) Platform into oncology. Our novel product offers a fully automated future-proof end-to-end solution that unlocks the full potential of Next Generation Sequencing (NGS) in the clinical oncology space. GenomOncology brings extensive experience in precision oncology care, and its platform has been developed specifically to deliver clinical informatics solutions for cancer. We look forward to working with GenomOncology to further drive precision medicine, delivering high quality patient care and shaping the future of human health.”

“Our partnership with Congenica enables us to expand opportunities for precision oncology care at the global level. The extensive information available within the GenomOncology Precision Oncology Platform, combined with the capabilities of the Congenica Clinical Decision Support Platform, will give clinicians and researchers the knowledge needed to provide their patients with the most appropriate care opportunities,” said Brad Wertz, Chief Executive Officer at GenomOncology.

About Congenica
Congenica is a digital health company enabling the rapid analysis and interpretation of genomic data, empowering researchers and clinicians to provide life-changing answers that improve wellbeing and disease management. Congenica’s world-leading software enables rapid genomic data analysis at scale and is the only product of its kind that has received the CE Mark under the In Vitro Diagnostics Directive.

A recognised leader in the genomic analysis of rare diseases and inherited cancer, Congenica is expanding its platform into new indications such as somatic cancer, next generation non- invasive pre-natal diagnosis and wellness, helping to deliver a future where clinical genomics is fully integrated into healthcare.

Based on pioneering research from the Wellcome Sanger Institute and the UK NHS, Congenica has a global footprint supporting leading international laboratories, academic medical centres and biopharmaceutical companies and is the exclusive Clinical Decision Support partner for the NHS Genomic Medicine Service.

www.congenica.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contacts
Becky Lamont, Marketing Communications Manager
00 44 (0)7468 698315
becky.lamont@congenica.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Dentalis Animal Health appoints Advisory Board4.2.2023 15:09:00 CET | Press release

Dentalis Animal Health, a company specializing in Oral Health care for companion animals, has announced the appointment of its Advisory Board. Michael Kelly Michael Kelly is an Animal Health Pharmaceutical Industry veteran with broad international business experience. A graduate of Harvard Business School and Cornell University, Michael was hired by Ciba-Geigy to begin his post graduate career in Switzerland. Eventually ending up in the Novartis Animal Health US Division (following the Ciba-Sandoz merger) he rose to CFO and VP of North America. In 2009 Kelly joined Piedmont Animal Health (PAH), a drug development company, and served various roles including CFO, COO and President. During his tenure at PAH the organization received more FDA Companion Animal Drug approvals than any other Company in the Industry. Dr Stephanie Livermore Dr. Stephanie Livermore has been practicing companion animal medicine and surgery since her graduation from the University of Guelph in 2008. Dr. Livermore

Autel Brings MaxiCharger DC Compact to eCarExpo and Signs Partnership Agreement with Leading Charging Operator Eways4.2.2023 09:00:00 CET | Press release

Autel, a leading provider of automotive electronics and diagnostic equipment and tools, exhibited for the first time at eCarExpo, the largest electric vehicles fair in the Nordic countries, on February 3-5, 2023, in Friends Arena, Stockholm. Autel brought its portfolio of products featuring the recently launched electric vehicle charger the MaxiCharger DC Compact. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230204005001/en/ Autel signs partnership agreement with leading charging operator Eways (Photo: Business Wire) As Autel's newly launched DC charger for EVs, the MaxiCharger DC Compact is not only sleek and compact with a 21.5-inch LCD touchscreen, but also powerful enough to provide up to 47kW of power for the European version. Either placed on a pedestal, or set on wheels for ultimate portability, the MaxiCharger DC Compact is perfect for charging operators wanting to provide their customers with a quick charge option

U.S. FDA Approves Takeda’s TAKHZYRO ® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older4.2.2023 00:48:00 CET | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the expanded use of TAKHZYRO® (lanadelumab-flyo) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in pediatric patients 2 to <12 years of age.1 Prior to today’s approval, the only approved routine prophylaxis treatment options for children 6 to <12 years of age required dosing every three to four days,and children with HAE 2 to <6 years of age had no approved prophylaxis treatment, making TAKHZYRO the first prophylaxis treatment for this age group.1-5 The recommended dose is 150 mg/1 mL solution in a single-dose prefilled syringe every four weeks in patients 2 to <6 years of age and every two weeks in patients 6 to <12 years of age.1 HAE attacks can involve serious and debilitating swelling in the abdomen, face, feet, genitals, hands and throat.5,7 Potentially fatal upper airway angioedema has been reported i

SLB Completes Acquisition of Gyrodata Incorporated3.2.2023 22:05:00 CET | Press release

SLB (NYSE: SLB) today announced it has completed the acquisition of Gyrodata Incorporated, a global company specializing in gyroscopic wellbore positioning and survey technology. The transaction will incorporate Gyrodata’s wellbore placement and surveying technologies within SLB’s Well Construction business, bringing customers innovative drilling solutions. This combination will improve wellbore quality and reduce drilling risk to unlock even the most remote and complex reservoirs. Integrating three-axis solid state gyro measurements with the latest SLB technological innovations will help ensure tighter trajectory control, reduce data acquisition time and improve the decision-making process—resulting in greater overall drilling efficiency. “I’m excited for this historic moment that will bring innovative solutions to the SLB Well Construction division and our industry,” said Jesus Lamas, president, Well Construction, SLB. “The technology-driven acquisition of Gyrodata is aligned with SL

Gallagher Re Joins ABIR and EY as 2023 Bermuda Risk Summit Headline Sponsors3.2.2023 16:17:00 CET | Press release

The Bermuda Business Development Agency (BDA) is pleased to announce that Gallagher Re has joined the Association of Bermuda Insurers and Reinsurers (ABIR) and EY as headline sponsors of the second annual Bermuda Risk Summit. Adam Schwebach, Executive Vice President, Gallagher Re, said, “Gallagher Re is proud to support the second Bermuda Risk Summit, an annual event that showcases the breadth and versatility of Bermuda’s globally significant risk market. This event serves as a timely opportunity to connect with industry leaders ahead of midyear renewals and we applaud the BDA for their efforts in making the Bermuda Risk Summit a success.” David Hart, BDA CEO, said, “We are just so excited to welcome Gallagher Re as our third and final headline sponsor, along with ABIR and EY. The theme of the 2023 Bermuda Risk Summit, being held from March 6-8, 2023, at the Hamilton Princess & Beach Club is ‘Innovation, Sustainability and Collaboration. We anticipate an even stronger attendance level

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom